Please assess the completion status of the following clinical trial:

Trial Title: Letrozole After Tamoxifen in Treating Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed primary invasive breast carcinoma resected at time of original diagnosis~  * No ductal carcinoma in situ~* Axillary lymph node negative, positive, or unknown~* No evidence of metastases~* No localized or distant breast cancer recurrence~* Not registered on protocol NCCTG-893052, any other IBCSG protocol, or protocol SWOG-S9623~* Hormone receptor status:~  * Estrogen or progesterone receptor positive as defined by tumor receptor content at least 10 fmol/mg protein or receptor positive by ERICA or PgRICA~ * Unknown status allowed if effort to determine status has been made by immunocytochemistry~* No contralateral breast cancer~PATIENT CHARACTERISTICS:~Age:~* Postmenopausal~Sex:~* Female~Menopausal status:~* Postmenopausal defined by one of the following:~  * Age 50 or over at start of adjuvant tamoxifen~ * Under age 50 and considered postmenopausal by treating physician at start of adjuvant tamoxifen~ * Under age 50 at start of adjuvant tamoxifen and had bilateral oophorectomy (surgical or radiation)~ * Under age 50 and premenopausal at start of adjuvant tamoxifen, but became amenorrheic during tamoxifen and remained amenorrheic for at least 1 year~ * Considered postmenopausal by physician with LH/FSH levels under the treatment center's postmenopausal limits~Performance status:~* ECOG 0-2~Life expectancy:~* At least 5 years~Hematopoietic:~* WBC ≥ 3,000/mm\^3 OR~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic:~* AST and/or ALT \< 2 times upper limit of normal (ULN) (unless imaging examinations have ruled out metastatic disease)~* Alkaline phosphatase \< 2 times ULN (unless imaging examinations have ruled out metastatic disease)~Renal:~* Not specified~Other:~* No concurrent medical or psychiatric condition that would preclude study participation~* No other malignancy within the past 5 years except adequately treated superficial squamous cell or basal cell skin cancer or carcinoma in situ of the cervix~* Able to swallow study drug~* Adequate oral intake~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior adjuvant chemotherapy allowed~* No concurrent chemotherapy~Endocrine therapy:~* Completed at least 4.5 but no more than 6 years of adjuvant tamoxifen after resection~* Completed at least 4.5-6 years of adjuvant aromatase inhibitor as initial therapy or after tamoxifen~* No more than 3 months since prior adjuvant tamoxifen~* No concurrent hormone replacement therapy (e.g., megestrol)~* No concurrent selective estrogen-receptor modulators (e.g., raloxifene or idoxifene)~* Concurrent intermittent vaginal estrogens (e.g., Estring) allowed if other local measures for intractable vaginal atrophy are insufficient~* No other concurrent aromatase inhibitors~* No more than 2 years since prior aromatase inhibitor therapy (re-randomization)~Radiotherapy:~* Prior radiotherapy allowed~Surgery:~* See Disease Characteristics~Other:~* At least 1 month since prior investigational drugs~* Prior treatment on a clinical trial for breast cancer allowed if permission has been obtained from the sponsors of the original study for their patient to participate on MA.17/JMA.17/BIG-97-01~* No prior placebo on core protocol~* No concurrent anticancer therapy~* Concurrent thyroid medication, calcium, vitamin D, and bisphosphonates allowed

- Gender: FEMALE
- Minimum Age: 0 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral letrozole once daily.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).